Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Certara, Inc. (NASDAQ:CERT)

Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Certara, Inc. (NASDAQ:CERT – Get Rating) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,548 shares of the company’s stock, valued at approximately $167,000.

Other institutional investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC acquired a new position in Certara during the third quarter worth approximately $95,000. Captrust Financial Advisors grew its position in shares of Certara by 135.8% in the first quarter. Captrust Financial Advisors now owns 4,628 shares of the company’s stock valued at $99,000 after purchasing an additional 2,665 shares during the last quarter. MetLife Investment Management LLC acquired a new position in shares of Certara in the first quarter valued at approximately $111,000. Heritage Wealth Management LLC acquired a new position in shares of Certara in the second quarter valued at approximately $117,000. Finally, PNC Financial Services Group Inc. grew its position in shares of Certara by 18.3% in the first quarter. PNC Financial Services Group Inc. now owns 5,841 shares of the company’s stock valued at $126,000 after purchasing an additional 905 shares during the last quarter. Institutional investors and hedge funds own 75.45% of the company’s stock.

Insiders Place Their Bets

In other Certara news, major shareholder Avatar Parent L.P. Eqt sold 29,954,521 shares of the company’s stock in a transaction on Thursday, December 8th. The stock was sold at an average price of $15.00, for a total transaction of $449,317,815.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.02% of the company’s stock.

Analyst Upgrades and Downgrades

CERT has been the topic of several research reports. Robert W. Baird downgraded Certara from an “outperform” rating to a “neutral” rating and upped their target price for the company from $17.00 to $19.00 in a research report on Wednesday, December 14th. Barclays upped their target price on Certara from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Credit Suisse Group upped their target price on Certara from $20.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Certara has an average rating of “Moderate Buy” and a consensus price target of $22.29.

Certara Trading Up 17.3 %

Shares of CERT stock opened at $21.63 on Friday. The company has a current ratio of 3.99, a quick ratio of 3.99 and a debt-to-equity ratio of 0.28. The stock has a market cap of $3.45 billion, a P/E ratio of -721.00, a price-to-earnings-growth ratio of 1.23 and a beta of 1.45. The stock has a 50 day simple moving average of $18.05 and a 200 day simple moving average of $15.87. Certara, Inc. has a 1 year low of $10.60 and a 1 year high of $24.66.

Certara (NASDAQ:CERT – Get Rating) last released its earnings results on Wednesday, March 1st. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.14 by ($0.01). Certara had a positive return on equity of 4.25% and a negative net margin of 1.28%. The business had revenue of $86.60 million for the quarter, compared to the consensus estimate of $82.55 million. During the same quarter in the previous year, the company earned $0.01 earnings per share. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, research analysts predict that Certara, Inc. will post 0.29 earnings per share for the current fiscal year.

Certara Company Profile

(Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.